Fernwood Investment Management LLC Sells 1,175 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Fernwood Investment Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 19,017 shares of the biopharmaceutical company’s stock after selling 1,175 shares during the period. Fernwood Investment Management LLC’s holdings in Gilead Sciences were worth $1,541,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Altfest L J & Co. Inc. bought a new position in Gilead Sciences during the 4th quarter valued at about $210,000. Federated Hermes Inc. increased its position in Gilead Sciences by 4.9% in the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after acquiring an additional 175,925 shares in the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at about $74,000. Abundance Wealth Counselors acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $1,881,000. Finally, HTLF Bank acquired a new stake in Gilead Sciences in the 4th quarter valued at about $253,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 0.8 %

GILD traded up $0.52 during trading on Monday, reaching $65.94. 7,838,371 shares of the stock were exchanged, compared to its average volume of 7,481,456. The stock has a market cap of $82.10 billion, a P/E ratio of 184.72, a price-to-earnings-growth ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a twelve month low of $64.63 and a twelve month high of $87.86. The stock’s 50 day moving average price is $71.28 and its two-hundred day moving average price is $76.25. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.37 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post 3.82 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.67%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research report on Wednesday, April 24th. Mizuho lowered their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Oppenheimer reiterated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Finally, Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average price target of $83.60.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.